uniQure N.V.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| QURE | MRVI | RARE | SLDB | DSGN | PGEN | |
|---|---|---|---|---|---|---|
| Market cap | 1.62B | 2.86B | 1.75B | 699.11M | 665.24M | 1.81B |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -7.8 | -76.7 | 76.1 | -3.8 | -6.6 | -23.0 |
| Price/book | 7.2 | 5.3 | -5.8 | 2.9 | 3.0 | 85.7 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −16.28% | +167.13% | −44.56% | +54.69% | +54.73% | +29.08% |
| Today | −3.52% | +3.62% | +3.19% | +3.82% | +2.80% | −3.71% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All QURE news ›uniQure reports US$768.4M liquidity and runway into 2030
Cash and investments fell US$41.9 million over the quarter as the gene therapy developer prepared for a potential AMT-130 launch. Operations are expected to be funded into 2030 as uniQure N.V. NASDAQQURE reported US$768.4 million in cash…
uniQure Announces Third Quarter 2026 Financial Results and Provides Company Update
~ FDA granted priority review of BLA for ifezuntirgene inilparvovec (AMT-130) in Huntington’s disease; PDUFA target action date of May 1, 2027 ~ ~ Aligned with FDA on key elements of confirmatory study design; U.S. patient screening…
Q3 earnings roll on, FDA pushes rare disease, uniQure’s Huntington’s therapy reaches review
> Listen on Spotify > Listen on Apple Products > Listen on Amazon Music > Listen on iHeart > Watch on YouTube Big Pharma earnings continued over the past week, with no fewer than a dozen companies reporting third quarter results, including…
uniQure: The Market May Be Misreading The AMT-130 Four-Year Data (Rating Upgrade)
uniQure's AMT-130 data likely remains strong enough to support accelerated approval, which isn't priced into the stock at the moment. Read more on QURE stock here. uniQure's (QURE) trials and tribulations have continued in recent months,…
uniQure falls on long-term Huntington's gene therapy data
uniQure's gene therapy for Huntington's continued to slow disease progression over four years of follow-up in a clinical trial, but signs that efficacy may be starting to wane spooked investors. Shares in Nasdaq-listed uniQure were trading…
More from 1 other outlet
uniQure set for May FDA verdict on Huntington's gene therapy
uniQure chief executive Matt Kapusta. The FDA is due to deliver a decision on uniQure's gene therapy for neurodegenerative disorder Huntington's by 1st May next year, after granting a priority review for the candidate. The FDA's acceptance…
FDA grants priority review to gene therapy for Huntington’s
Final decision on ifezuntirgene inilparvovec expected by May 1 of next year Written by Steve Bryson, PhD | Nov. 3, 2026 The U.S. Food and Drug Administration (FDA) has agreed to review uniQure’s application seeking accelerated approval of…
More from 4 other outlets
- Mugglehead uniQure gains FDA priority review for Huntington's gene therapy
- AllSci FDA grants uniQure’s Huntington’s gene therapy Priority Review on small, externally controlled dataset
- @clin_trials FDA Accepts uniQure’s Huntington’s Disease Gene Therapy BLA for Priority Review
- Seeking Alpha uniQure gains FDA Priority Review for Huntington's disease gene therapy
FDA Sets May 1 PDUFA Action Date for uniQure’s Huntington’s Disease Gene Therapy
Agency accepts Biologics License Application for ifezuntirgene inilparvovec, sets Priority Review in reversal of earlier hardline stance and public criticism, following change in CBER leadership The FDA has set a May 1 target action date…
uniQure Announces FDA Acceptance and Priority Review of the Biologics License Application for ifezuntirgene inilparvovec for the Treatment of Huntington's Disease
New Upgrade: Dedicated Screeners for Stocks & ETFs ~ FDA sets PDUFA target action date of May 1, 2027 ~ ~ If approved, ifezuntirgene inilparvovec will be the world’s first disease-modifying treatment for Huntington’s disease ~ The BLA is…
Alnylam Pharmaceuticals, Inc. (ALNY) RNAi Roundtable: Exon 1 Targeting With Brezosiran for Huntington's Disease Transcript
Alnylam Pharmaceuticals, Inc. (ALNY) RNAi Roundtable: Exon 1 Targeting With Brezosiran for Huntington's Disease October 26, 2026 10:00 AM EDTCompany... Alnylam Pharmaceuticals, Inc. (ALNY) RNAi Roundtable: Exon 1 Targeting With Brezosiran…
From the 4Search news index, newest first.